Transfusion Medicine Reviews
Volume 23, Issue 3 , Pages 177-188 , July 2009

Cryoprecipitate: The Current State of Knowledge

  • Jeannie L. Callum

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Jeannie L. Callum, BA, MD, FRCPC, CTBS, B204, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, Ontario, Canada M4N 3M5.
    • ,
  • Keyvan Karkouti
    • ,
  • Yulia Lin

References 

  1. Pool JG, Hershgold EJ, Pappenhagen AR. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature. 1964;203:312
  2. Pool JG. Preparation and testing of antihemophilic globulin (factor VIII) sources for transfusion therapy in hemophilia. Description of a new sterile concentrate process for blood banks. Scand J Clin Lab Invest. 1965;17:70–77
  3. Bennett E, Dormandy K. Pool's cryoprecipitate and exhausted plasma in the treatment of von Willebrand's disease and factor-XI deficiency. Lancet. 1966;2:731–732
  4. Barrett KE, Israëls MC, Burn AM. The effect of cryoprecipitate concentrate in patients with classical hemophilia. Lancet. 1967;1:191–192
  5. Brecher ME. American Association of Blood Banks Technical Manual. ed 15. Bethesda (Md): American Association of Blood Banks; 2005;
  6. Allain JP. Non–factor VIII related constituents in concentrates. Scand J Haematol. 1984;33:173–180(suppl 41)
  7. Poon MC. Cryoprecipitate: Uses and alternatives. Transfus Med Rev. 1993;7:180–192
  8. Romans R: Canadian Blood Services. Personal communication
  9. American Association of Blood Banks . Standards for Blood Banks and Transfusion Services. ed 25. Bethesda (Md): American Association of Blood Banks; 2008;
  10. Klein HG, Anstee DJ. Mollison's Blood Transfusion in Clinical Medicine. ed 11. Malden (Mass): Wiley-Blackwell; 2005;
  11. van Gastel C, Sixma JJ, Borst-Eilers E, et al. Preparation and infusion of cryoprecipitate from exercised donors. Br J Haematol. 1973;25:461–466
  12. Kasper CK, Myhre BA, McDonald JD, et al. Determinants of factor VIII recovery in cryoprecipitate. Transfusion. 1975;15:312–322
  13. Kreuz W, Meili E, Peter-Salonen K, et al. Pharmacokinetic properties of a pasteurised fibrinogen concentrate. Transfus Apheresis Sci. 2005;32:239–244
  14. Lundberg GD. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets: Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. JAMA. 1994;271:777–781
  15. Saxena S, Odono V, Francis RB, et al. Can storage of thawed cryoprecipitate be extended to more than six hours?. Am J Clin Pathol. 1990;94:203–206
  16. Lovejoy AE, Reynolds TC, Visich JE, et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood. 2006;108:57–62
  17. Board PG, Losowsky MS, Miloszewski KJ. Factor XIII: Inherited and acquired deficiency. Blood Rev. 1993;7:229–242
  18. Saba TM, Jaffe E. Plasma fibronectin (opsonic glycoprotein): Its synthesis by vascular endothelial cells and role in cardiopulmonary integrity after trauma are related to reticuloendothelial function. Am J Med. 1980;68:577–594
  19. Reilly JT, McVerry BA, Mackie MJ. Fibronectin in blood products—An in vitro and in vivo study. J Clin Pathol. 1983;36:1377–1381
  20. McVerry BA, Machin SJ. Incidence of allo-immunization and allergic reactions to cryoprecipitate in haemophilia. Vox Sang. 1979;36:77–80
  21. George JN, Pickett EB, Heinz R. Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate. Blood. 1986;68:307–309
  22. Ardoin SP, Shanahan JC, Pisetsky DS. The role of microparticles in inflammation and thrombosis. Scand J Immunol. 2007;66:159–165
  23. Burman D, Hodson AK, Wood CBS, et al. Acute anaphylaxis, pulmonary oedema, and intravascular haemolysis due to cryoprecipitate. Arch Dis Child. 1973;48:483–485
  24. Canadian Blood Services . Circular of information for the use of human blood and blood components 2005. Ottawa (ON): Canadian Blood Services; 2005;
  25. American Association of Blood Banks . Blood Transfusion Therapy: A Physician's Handbook. ed 7. Bethesda (Md): American Red Cross; 2002;
  26. Canadian Standards Association . CSA Z902: Blood and blood components. Mississauga (ON): Canadian Standards Association; 2004;http://www.wales.nhs.uk/documents/WHC_2005_066.pdf
  27. http://hospital.blood.co.uk/library/pdf/mailout_september07.pdfNational Blood Service, Bulletin, 27th Sept, 2007
  28. http://www.transfusionguidelines.org/docs/pdfs/oig_report.pdf
  29. Salter D, Lloyd A. EU Blood Directive—blood safety and quality regulations 2005. Welsh Health Circ. 2005;http://www.wales.nhs.uk/documents/WHC_2005_066.pdf
  30. Alport EC, Callum JL, Nahirniak S, et al. Cryoprecipitate use in 25 Canadian hospitals: Commonly used outside of published guidelines. Transfusion. 2008;48:2122–2127
  31. Ketchum L, Hess JR, Hiippala S. Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma. J Trauma. 2006;60:S51–S58(6 Suppl)
  32. Ho AM, Karmakar MK, Dion PW. Are we giving enough coagulation factors during major trauma resuscitation?. Am J Surg. 2005;190:479–484
  33. Stinger HK, Spinella PC, Perkins JG, et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma. 2008;64:S79–S85(2 Suppl)
  34. Cinat ME, Wallace WC, Nastanski F, et al. Improved survival following massive transfusion in patients who have undergone trauma. Arch Surg. 1999;134:964–968
  35. Counts RB, Haisch C, Simon TL, et al. Hemostasis in massively transfused trauma patients. Ann Surg. 1979;190:91–99
  36. Mannucci PM, Federici AB, Sirchia G. Hemostasis testing during massive blood replacement: A study of 172 cases. Vox Sang. 1982;42:113–123
  37. Ciavarella D, Reed RL, Counts RB, et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol. 1987;67:365–368
  38. Hewson JR, Neame PB, Kumar N, et al. Coagulopathy related to dilution and hypotension during massive transfusion. Crit Care Med. 1985;13:387–391
  39. Phillips TF, Soulier G, Wilson RF. Outcome of massive transfusion exceeding two blood volumes in trauma and emergency surgery. J Trauma. 1987;27:903–910
  40. Horst HM, Dlugos S, Fath JJ, et al. Coagulopathy and intraoperative blood salvage (IBS). J Trauma. 1992;32:646–652
  41. Faringer PD, Mullins RJ, Johnson RL, et al. Blood component supplementation during massive transfusion of AS-1 red cells in trauma patients. J Trauma. 1993;34:481–485
  42. Singbartl K, Innerhofer P, Radvan J, et al. Hemostasis and hemodilution: A quantitative mathematical guide for clinical practice. Anesth Analg. 2003;96:929–935
  43. Hirshberg A, Dugas M, Banez EI, et al. Minimizing dilutional coagulopathy in exsanguinating hemorrhage: A computer simulation. J Trauma. 2003;54:454–463
  44. Delgado-Rodriguez M, Llorca J. Bias. J Epidemiol Community Health. 2004;58:635–641
  45. Horsey PJ. Multiple trauma and massive transfusion. Anaesthesia. 1997;52:1027–1029
  46. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11–28
  47. Lal AB, Maruthavanan R, Scott NB, et al. Aortic valve repair in a patient with congenital afibrinogenemia. Anesth Analg. 2005;101:1628–1630
  48. Rodriguez RC, Buchanan GR, Clanton MS. Prophylactic cryoprecipitate in congenital afibrinogenemia. Clin Pediatr (Phila). 1988;27:543–545
  49. Thompson HW, Touris S, Giambartolomei S, et al. Treatment of congenital afibrinogenemia with cryoprecipitate collected through a plasmapheresis program using dedicated donors. J Clin Apheresis. 1998;13:143–145
  50. Kreuz W, Meili E, Peter-Salonen K, et al. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apheresis Sci. 2005;32:247–253
  51. Bengtson JM, VanMarter LJ, Barss VA, et al. Pregnancy outcome after premature rupture of the membranes at or before 26 weeks' gestation. Obstet Gynecol. 1989;73:921–927
  52. Rotschild A, Ling EW, Puterman ML, et al. Neonatal outcome after prolonged preterm rupture of the membranes. Am J Obstet Gynecol. 1990;162:46–52
  53. Quintero RA, Morales WJ, Allen M, et al. Treatment of iatrogenic previable premature rupture of membranes with intra-amniotic injection of platelets and cryoprecipitate (amniopatch): Preliminary experience. Am J Obstet Gynecol. 1999;181:744–749
  54. Sipurzynski-Budrass S, Macher S, Haeusler M, et al. Successful treatment of premature rupture of membranes after genetic amniocentesis by intra-amniotic injection of platelets and cryoprecipitate (amniopatch): A case report. Vox Sang. 2006;91:88–90
  55. Sciscione AC, Manley JS, Pollock M, et al. Intracervical fibrin sealants: A potential treatment for early preterm premature rupture of the membranes. Am J Obstet Gynecol. 2001;184:368–373
  56. French CJ, Bellomo R, Angus P. Cryoprecipitate for the correction of coagulopathy associated with liver disease. Anaesth Intensive Care. 2003;31:357–361
  57. Nugent DJ. Prophylaxis in rare coagulation disorders—Factor XIII deficiency. Thromb Res. 2006;118:S23–S28(Suppl 1)
  58. Rodeghiero F, Castaman G, Meyer D, et al. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang. 1992;62:193–199
  59. Perkins HA. Correction of the hemostatic defects in von Willebrand's disease. Blood. 1967;30:375–380
  60. Blatt PM, Brinkhous KM, Culp HR, et al. Anti-hemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. JAMA. 1976;236:2770–2772
  61. Califf RM, Topol EJ, George BS, et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in the treatment of acute myocardial infarction. Am J Med. 1988;85:353–359
  62. Verstraete M, Bernard R, Bory M, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. Lancet. 1985;1:842–847
  63. Sane DC, Califf RM, Topol EJ, et al. Bleeding during thrombolytic therapy for acute myocardial infarction: Mechanisms and management. Ann Intern Med. 1989;111:1010–1022
  64. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial—phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1–11
  65. Lupinetti FM, Stoney WS, Alford WC, et al. Cryoprecipitate-topical thrombin glue. Initial experience in patients undergoing cardiac operations. J Thorac Cardiovasc Surg. 1985;90:502–505
  66. Carless PA, Anthony DM, Henry DA. Systematic review of the use of fibrin sealant to minimize perioperative allogeneic blood transfusion. Br J Surg. 2002;89:695–703
  67. Carless PA, Henry DA, Anthony DM. Fibrin sealant use for minimising peri-operative allogeneic blood transfusion. Cochrane Database Syst Rev. 2003;2:CD004171
  68. Figueras J, Llado L, Miro M, et al. Application of fibrin glue sealant after hepatectomy does not seem justified: Results of a randomized study in 300 patients. Ann Surg. 2007;245:536–542
  69. Noris M, Remuzzi G. Uremic bleeding: Closing the circle after 30 years of controversies?. Blood. 1999;94:2569–2574
  70. Livio M, Gotti E, Marchesi D, et al. Uraemic bleeding: Role of anaemia and beneficial effect of red blood cell transfusions. Lancet. 1982;2:1013–1015
  71. Janson PA, Jubelirer SJ, Weinstein MJ, et al. Treatment of bleeding tendency in uremia with cryoprecipitate. N Engl J Med. 1980;303:1318–1322
  72. Triulzi DJ, Blumberg N. Variability in response to cryoprecipitate treatment for hemostatic defects in uremia. Yale J Biol Med. 1990;63:1–7
  73. Gilbert WM, Danielsen B. Amniotic fluid embolism: Decreased mortality in a population-based study. Obstet Gynecol. 1999;93:973–977
  74. Tuffnell DJ. Amniotic fluid embolism. Curr Opin Obstet Gynecol. 2003;15:119–122
  75. Rodgers GP, Heymach GJ. Cryoprecipitate therapy in amniotic fluid embolization. Am J Med. 1984;76:916–920
  76. Rodgers GP, Heymach GJ. Amniotic fluid embolism. JAMA. 1986;256:1892–1893
  77. Boyer LV, Seifert SA, Clark RF, et al. Recurrent and persistent coagulopathy following pit viper envenomation. Arch Intern Med. 1999;159:706–710
  78. Robinson RF, Baker RS, Martin S, et al. Use of “Near Middle East Antivenom” to treat African bush viper envenomation. Vet Hum Toxicol. 2004;46:264–265
  79. Weis JR, Whatley RE, Glenn JL, et al. Prolonged hypofibrinogenemia and protein C activation after envenoming by Echis carinatus sochureki. Am J Trop Med Hyg. 1991;44:452–460
  80. Ferguson LA, Morling A, Moraes C, et al. Investigation of coagulopathy in three cases of tiger snake (Notechis ater occidentalis) envenomation. Pathology. 2002;34:157–161
  81. McNally T, Conway GS, Jackson L, et al. Accidental envenoming by a Gaboon viper (Bitis gabonica): The haemostatic disturbances observed and investigation of in vitro haemostatic properties of whole venom. Trans R Soc Trop Med Hyg. 1993;87:66–70
  82. Kornalik F, Vorlová Z. Non-specific therapy of a hemorrhagic diathesis after a bite by a young Bothrops asper (barba amarilla): A case report. Toxicon. 1990;28:1497–1501
  83. Saba TM, Blumenstock FA, Shah DM, et al. Reversal of fibronectin and opsonic deficiency in patients: A controlled study. Ann Surg. 1984;199:87–96
  84. Kuusela P. Fibronectin binds to Staphylococcus aureus. Nature. 1978;276:718–720
  85. Scovill WA, Saba TM, Kaplan JE, et al. Disturbances in circulating opsonic activity in man after operative and blunt trauma. J Surg Res. 1977;22:709–716
  86. Scovill WA, Saba TM, Kaplan JE, et al. Deficits in reticuloendothelial humoral control mechanisms in patients after trauma. J Trauma. 1976;16:898–904
  87. Stainsby D, MacLennan S, Thomas D, et al. Guidelines on the management of massive blood loss. Br J Haematol. 2006;135:634–641
  88. Droubatchevskaia N, Wong MP, Chipperfield KM, et al. Guidelines for cryoprecipitate transfusion. BC Med J. 2007;49:441–445
  89. Hedges SJ, Dehoney SB, Hooper JS, et al. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract. 2007;3:138–152
  90. Canadian Society for Transfusion Medicine. Canadian Standards for Transfusion Medicine (version 2). Ottawa (ON): Canadian Society for Transfusion Medicine; 2007;
  91. Council of Europe . Guide to the preparation, use an quality assurance of blood components. ed 12. Strasbourg: Council of Europe Publishing; 2006;
  92. Hensley MJ. Use and misuse of cryoprecipitate (letter). N Engl J Med. 1975;292:1299
  93. Schofield WN, Rubin GL, Dean MG. Appropriateness of platelet, fresh frozen plasma and cryoprecipitate transfusion in New South Wales public hospitals. Med J Aust. 2003;178:117–121
  94. Pantanowitz L, Kruskall MS, Uhl L. Cryoprecipitate: Patterns of use. Am J Clin Pathol. 2003;119:874–881
  95. Robillard P, Nawej KI, Jochem K. The Quebec hemovigilance system: Description and results from the first two years. Transfus Apheresis Sci. 2004;31:111–122
  96. McVerry BA, Machin SJ. Incidence of allo-immunization and allergic reactions to cryoprecipitate in haemophilia. Vox Sang. 1979;36:77–80
  97. Reese EP, McCullough JJ, Craddock PR. An adverse pulmonary reaction to cryoprecipitate in a haemophiliac. Transfusion. 1975;15:583–588
  98. Musa MO, Al-Fair F, Al-Mohareb F, et al. Cryoprecipitate-induced mesenteric vein thrombosis during l-asparaginase therapy for acute lymphocytic leukemia. Leuk Lymph. 2001;40:429–431
  99. Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol. 2007;138:430–445
  100. Aygoren-Pursun E, Martinez Saguer I, Rusicke E, et al. Retrochorionic hematoma in congenital afibrinogenemia: Resolution with fibrinogen concentrate infusions. Am J Hematol. 2007;82:317–320
  101. Yasunaga H. Risk of authoritarianism: Fibrinogen-transmitted hepatitis C in Japan. Lancet. 2007;370:2063–2067

PII: S0887-7963(09)00027-3

doi: 10.1016/j.tmrv.2009.03.001

Transfusion Medicine Reviews
Volume 23, Issue 3 , Pages 177-188 , July 2009

Article Tools